Kornimate/medical-research-clean huggingface dataset:
efficacy of seventh generation bonding agents as short-term desensitizers among patients with hypersensitivity

Conditions: Dentin Hypersensitivity

Summary: the world lacks a gold standard treatment for treating dentin hypersensitivity. fluoride varnish is most commonly used as a treatment but it causes temporary discoloration of tooth structure and may cause irritation or burning of gums when it comes in contact with gums. seventh generation bonding agents are less technique sensitive and are easy to use. the present study aims to find out the better seventh generation bonding agent as a treatment option for sensitivity. a total of 105 patients with dentin hypersensitivity are randomized into three groups. scaling and root debridement are performed for all the groups. this study compares two seventh generation bonding agents and taking fluoride varnish as control group.

dentin hypersensitivity is a painful condition resulting from external stimulation of exposed vital dentin. dentin gets exposed to the oral environment by multiple factors like gingival recession, erosion, attrition, abrasion, fractures, caries, and many more. the intra-tubular fluid movement of exposed tubules is believed to be the mechanism of hypersensitivity. dentin bonding agents acts by occluding patent tubules, thus reducing hypersensitivity. seventh generation combines etchant, primer and bonding agent into one solution and makes it easy to use. after diagnosis of dentin hypersensitivity, the patients signed a consent form stating their voluntary participation in the research. the discomfort internal scale score and schiff cold air sensitivity scale scores are recorded at baseline, immediately after the intervention, after 01 week and after 01 month. discomfort internal scale score are recorded for every participant using dental explorer in the mesial and distal direction on the exposed surface of the affected teeth for tactile stimulation. for schiff cold air sensitivity scale scores an air syringe system was used to check the evaporative response on the affected teeth of the participants and the scores are recorded. all the patients received scaling and root debridement as a standard protocol treatment. dentin bonding agents and fluoride varnish are applied to the participants. all the participants are instructed to fast for two hours after the treatment. all the records are made on subjective response of patients.

Eligibility criteria:
inclusion criteria: * healthy males or females of 18 to 45 years of age * hypersensitive teeth to air and tactile stimultaion * gingival recession of miller class i and ii * score 1 of silness and loe plaque index * participants who have no sysytemic illness * patients who agree to give consent were included in the study. exclusion criteria: * carious teeth * fractured restoration or cracked teeth * teeth undergoing orthodontic or periodontal treatment at sensitive site * patients who had dental bleaching in last 03 months * patients taking pain killers * smokers * pregnant and nursing females were excluded from the study

Keywords: dentin hypersensitivity gingival recession bonding agents
tobramycin injection to prevent infection in open fractures

Conditions: Wound Infection; Fractures, Open; Surgical Site Infection

Summary: the goal of open extremity fracture (oef) treatment is to promote fracture healing and restore function while preventing the development of infection. this is achieved through systematic and timely wound debridement and irrigation, fracture stabilization, tetanus prophylaxis, systemic and local antimicrobial therapy, and judicious timing of wound closure based on cleanliness. early prophylactic systemic antibiotics lower infection rates in open fractures but have limitations of achieving adequate concentration at the hypoperfused wound area. oef wounds are frequently poor in vasculature secondary to the soft tissue injury, hence adequate concentration of antibiotic cannot permeate to the tissue at risk. if systemic antibiotic concentrations are increased to achieve minimum inhibitory concentration (mic) for pathogens at the wound, there is heightened concern for systemic drug toxicity. in sharp contrast, locally administered antibiotics achieve high drug concentration directly within the wound cavity with minimal systemic side effects. local antibiotic therapy has shown to reduce rates of open fracture wound infection. with the serious implications of postoperative infections in oef, it is imperative that all measures including further use of prophylactic local antibiotics be considered to prevent fracture-related infection (fri). the overarching hypothesis for this project is that a novel synergistic combination of local aqueous tobramycin plus perioperative weight-based iv cephalosporin antibiotic prophylaxis will reduce the rate of fri one year after oef surgery. this in turn will improve oef patient outcomes, decreasing morbidity and return to the operating room (or) without any adverse effect on fracture healing. regardless of the treatment group, bacterial speciation will be determined for patients that do develop fri to help guide future treatment. the goal is to improve the clinical outcome and recovery of the population that sustains an oef by decreasing the rate of fri and fracture nonunions while concurrently educating on bacterial speciation and resistance.


Eligibility criteria:
inclusion criteria: * open fracture to arm, leg, or both * over the age of 18 exclusion criteria: * under the age of 18 * allergy to tobramycin or any other antibiotic in the aminoglycoside family * previously treated with a resorbable antibiotic carrier * pregnancy

Keywords: local antibiotic non-union aminoglycoside tobramycin open extremity fracture fracture related infection
predicting symptom trajectories after thoracoscopic lung cancer surgery using an interpretable machine learning model

Conditions: Lung Cancer

Summary: patients suffer from a variety of symptoms after thoracoscopic surgery. however, there is a lack of validated predictive tools to identify potentially high-risk patients. this study is anticipated to include approximately 1,500 lung cancer patients who undergo thoracoscopic surgery. latent class mixed modeling (lcmm) will be used to dentify subgroups of patients with similar symptom trajectories. machine learning models were developed to predict postoperative symptom trajectories based on collected information. effective prediction of postoperative symptoms can help identify high-risk patients and take preventive measures.

thoracoscopic lung cancer surgery is a widely utilized approach for treating early and locally advanced lung cancer. despite the advantages of thoracoscopic surgery, such as minimal invasion and rapid recovery, patients still suffer from a variety of symptoms such as pain, shortness of breath, sleep disorders or fatigue after surgery, which seriously affects the quality of life. however, there is a lack of validated predictive tools to identify potentially high-risk patients. this study is anticipated to include approximately 1,500 lung cancer patients who undergo thoracoscopic surgery. patients are invited to fill out the md anderson symptom inventory-lung cancer module after thoracoscopic surgery. symptoms of interest include pain, shortness of breath, sleep disturbance, and fatigue. moderate to severe symptoms were defined as a score of ≥ 4. latent class mixed modeling (lcmm), a clustering technique, can identify subgroups of patients with similar symptom trajectories based on longitudinal patient-reported outcome (pro) data. machine learning models were developed to predict postoperative symptom trajectories based on collected information including demographic and clinical information, and operative data. the machine learning models mainly include random forest, support vector machines, neural networks, xgboost, etc. the most appropriate model is selected, and model interpretation is performed using the shap method. effective prediction of postoperative symptoms can help identify high-risk patients and take preventive measures.

Eligibility criteria:
inclusion criteria: * age 18-80 years old; * pathologically diagnosed lung cancer; * undergo thoracoscopic surgery, including video-assisted thoracoscopy and robotic-assisted thoracoscopic surgery; * no prior history of malignancy or lung surgery; * have the ability to complete the scale. exclusion criteria: * converted to thoracotomy during thoracoscopic surgery; * unable to complete the postoperative scale at least two times; * missing data values exceeding 30 percent.

Keywords: lung cancer machine learning patient-reported outcome thoracoscopy surgery
myocardial perfusion imaging by combined 15o-h2o pet and mr

Conditions: Ischemic Heart Disease

Summary: the trial will include 75 patients with evident or suspected ischemic heart disease refered to department of nuclear medicine \& pet centre, aarhus university hospital, for perfusion imaging by 15o-h2o pet/ct scan of the heart during rest and stress. instead of the clinical scan participants will undergo perfusion imaging by 15o-h2o pet/mr. the clinician will receive diagnostic information based on the 15o-h2o pet scan as if the patient had not participated in the study. as such, the study has no influence on the diagnostics or treatments of the patient. data from the scans will be used to compare 15o-h2o pet with cardiac mr for evaluation of myocardial perfusion. follow up will be done for up to 10 years in regards to major cardiovascular events in order to determine the prognostic value of the scan.


Eligibility criteria:
inclusion criteria: * refered for myocardial perfusion imaging by o15-h2o pet at department of nuclear medicine \& pet centre, aarhus university hospital * \> 18 years of age exclusion criteria: * allergic to adenosine * allergic to gadolinium * pregnancy * claustrophobia * severe asthma * pacemaker or other ferro-magnetic implants * gfr \< 30

Keywords: myocardial perfusion imaging positron-emission tomography cardiac magnetic resonance imaging coronary artery disease coronary flow reserve myocardial blood flow
early diagnosis of asthma in young children

Conditions: Asthma

Summary: the overall aim of the study is an early asthma diagnosis in young children by the use of non-invasive biomarkers of airway inflammation /oxidative stress in exhaled air, and early lung function measurements


Eligibility criteria:
inclusion criteria: * children aged 2-3 years, with recurrent respiratory symptoms suggestive of asthma * children aged 2-3 years, with no or minor respiratory symptoms exclusion criteria: * mental retardation * cardiac anomalies * congenital malformations * other diseases of the lungs/airways * chronic systemic inflammatory diseases like m. crohn * the inability to perform lung function measurements and/or exhaled air collection

Keywords: asthma transient wheezing early diagnosis exhaled air nitrogen monoxide airway resistance
incidence of neurogenic paraosteoarthropathies in a population of brain traumatized and spinal cord injured patients and specific markers of early npoa development"

Conditions: Spinal Cord Injuries; Injury, Brain, Traumatic

Summary: neurogenic paraosteoarthropathies are peri-articular bone formations that may occur as a result of central neurological injury. their occurrence limits reeducation and recovery capacities. neurogenic paraosteoarthropathies sometimes cause complications (pain, joint stiffness, vascular and nerve compression, pressure sores) in patients already suffering from severe neurological sequelae affecting functional prognosis. a lot of clinical research work has been carried out within dr salga team. subsequently, a collaboration was born with fundamental research teams (pr levesque, pr le bousse kerdilès, pr banzet, pr genêt) allowing translational work between humans and animals. the clinical application of recent research findings now makes it possible to launch the very first prospective study on neurogenic paraosteoarthropathies.

based on the results of collaborative and translational (human-animal) work, investigators wish to conduct the first prospective study that would allow: (i) to assess the incidence of neurogenic paraosteoarthropathies (clinical suspicion and radiological confirmation). the prospective nature of this clinical data collection will make it possible to avoid the biases attributed to the retrospective studies conducted to date. ii) early detection of patients at risk of developing neurogenic paraosteoarthropathies, using specific biomarkers and clinical parameters. early diagnosis could prevent complications and functional impact of neurogenic paraosteoarthropathies. investigators have chosen to restrict population to patients most at risk of developing neurogenic paraosteoarthropathies as a result of the central neurological event in order to have 2 populations appear at the end of the study: a population with neurogenic paraosteoarthropathies and a population without neurogenic paraosteoarthropathies that can be compared.

Eligibility criteria:
inclusion criteria: * male or female \> 18 years old, * brain trauma with initial glasgow score \< 8, * or brain trauma with an initial glasgow score between 8 and 14 associated with an injury severity score (iss) \> 15 and surgery within 24 hours of admission or traumatic spinal cord injury with complete neurological impairment (initial para/tetraplegia), * complete traumatic spinal cord injury. accident less than 48 hours old * informed consent signed by the patient or a family member exclusion criteria: * age \< 18 years, * hemorrhagic shock or blood transfusion greater than or equal to 4 red blood cells within 6 hours of the trauma (also include pre-hospital or first hospital red blood cells) * follow-up impossible over one year, * patient not living in the paris region, * pregnant or breastfeeding woman, * patient under guardianship or curatorship, * no affiliation to a social security scheme or universal mutual fund.
telavancin for treatment of uncomplicated staphylococcus aureus bacteremia

Conditions: Gram-Positive Bacterial Infections

Summary: the purpose of this study is to determine whether telavancin (td-6424, arbelic) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.


Eligibility criteria:
inclusion criteria - documented s. aureus bacteremia exclusion criteria - patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. the following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid
cci-779 in treating patients with locally advanced or metastatic pancreatic cancer

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer

Summary: drugs used in chemotherapy, such as cci-779, work in different ways to stop tumor cells from dividing so they stop growing or die. this phase ii trial is studying how well cci-779 works in treating patients with locally advanced or metastatic pancreatic cancer

primary objectives: i. determine the overall survival at 6 months in patients with locally advanced or metastatic pancreatic cancer treated with cci-779. secondary objectives: i. determine time to progression, progression-free survival, overall survival, and tumor response rate in patients with measurable disease treated with this drug. ii. correlate biomarkers of response with clinical response in patients treated with this drug. iii. determine the safety and toxicity of this drug in these patients. outline: this is an open-label study. patients receive cci-779 iv over 30 minutes once weekly. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months. projected accrual: a total of 40 patients will be accrued for this study within 13 months.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the pancreas * locally advanced or metastatic disease * radiographic evidence of disease * no known brain metastases * performance status - ecog 0-2 * more than 3 months * wbc ≥ 3,000/mm\^3 * absolute neutrophil count ≥ 1,500/mm\^3 * platelet count ≥ 100,000/mm\^3 * bilirubin ≤ 1.5 times upper limit of normal (uln) * ast and alt ≤ 2.5 times uln (5 times uln if liver metastases are present) * creatinine ≤ 1.5 mg/dl * creatinine clearance ≥ 50 ml/min * no symptomatic congestive heart failure * no unstable angina pectoris * no cardiac arrhythmia * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * fasting serum cholesterol ≤ 350 mg/dl * fasting triglycerides ≤ 400 mg/dl * no ongoing or active infection * no psychiatric illness or social situation that would preclude study compliance * no other concurrent uncontrolled illness * no concurrent prophylactic hematopoietic colony-stimulating factors * no prior chemotherapy for metastatic pancreatic cancer * more than 2 months since prior adjuvant or neoadjuvant chemoradiotherapy for resected pancreatic cancer * must have radiographic evidence of recurrent disease * more than 2 months since prior chemoradiotherapy for locally advanced pancreatic cancer * must have radiographic evidence of disease progression * see chemotherapy * see chemotherapy * no other concurrent investigational or commercial agents or therapies for the malignancy * no other concurrent anticancer therapy * no concurrent combination antiretroviral therapy for hiv-positive patients
non-inferiority, open-label, multicenter and randomized clinical trial about the treatment of mild to moderate persistent allergic rhinitis

Conditions: Allergic Rhinitis

Summary: to assess the efficacy of the study product noex in the treatment of allergic rhinitis by means of the nasal index score (nis) after 4 weeks of treatment with the drug.

primary objective: to assess the efficacy of the study product noex in the treatment of allergic rhinitis by means of the nasal index score (nis) after 4 weeks of treatment with the drug. secondary objectives: to determine the total nis scale score after 12 weeks of treatment and the scores of the same scale individually for the symptoms of nasal obstruction, coryza, sneezing and nasal pruritus after 4 and 12 weeks of treatment, as well as to assess the safety of the study product according to the presence of adverse events. some eligibility criteria: * nis scale score \> 4 points at the randomization visit * patients with persistent mild to moderate ar, according to the aria criteria with indication for use budesonide;

Eligibility criteria:
inclusion criteria: * sign the informed consent form or - in case of patients younger than 18 years, the legal responsible must sign the consent; * ≥ 12 years old; * nis scale score \> 4 points at the randomization visit * patients with persistent mild to moderate ar, according to the aria criteria (see appendix b), with indication for use budesonide; * positive skin test for at least one relevant airborne agent; * ar symptoms for at least 2 years; * may undergo a washout period of at least 2 weeks (without using any oral, nasal or inhalant corticosteroid agent; see 6.4). exclusion criteria: * patients with persistent severe allergic rhinitis; * patients with severe co-morbidities (at the investigator's opinion); * patients with moderate to severe persistent asthma; * clinical history of infection of the airways 30 days before the study entry; * patients with structural changes causing nasal obstruction, such as pronounced nasal septum deviation, nasal polyps or any other type of nasal malformation; * pregnant women and patients planning to become pregnant during the study period or breastfeeding women; * patients in need of other drugs to treat the allergic rhinitis, such as anti-immunoglobulin e, allergen-specific immunotherapy, anti-leukotrienes, systemic vasoconstrictors, oral corticosteroids and other inhalant corticosteroids. patients using allergen-specific immunotherapy during the last year, as well as using anti-leukotrienes and anti-immunoglobulin e during the last month, or even patients using inhalant or oral corticosteroids after v0 will not be enrolled in the study.
patient report outcome and oncological safety -oncoplastic and conventional bcs cohort

Conditions: Patient Reported Outcome; Oncological Safety; Breast-conserving Surgery; Breast Cancer Female

Summary: breast-conserving surgery (bcs) is the traditional surgical treatment for early-stage breast cancer patients. there are evidences indicating that oncoplastic bcs could improve cosmetic outcomes and/or quality of life, and has similar oncological safety as conventional bcs does. however, these studies that focused on patient-reported outcomes and oncological safety were mainly from one institution or of small sample size. the variations across hospitals and regions were not fully analyzed. a multicenter prospective patient report outcome (pros) and oncological safety will be planned to assess the pros and safety for chinese breast cancer patients who will undergo oncoplastic and conventional breast-conserving surgery (obcs). this study follows the helsinki declaration and chinese rules. all patients will be asked to sign the informed consent and will be followed up 24 months after operations. all data will be collected.


Eligibility criteria:
inclusion criteria: 1. informed consent signed; 2. non-metastatic breast cancer patients confirmed by pathology; 3. adult (\>18 years old, \<80 years old); 4. female; 5. must undergo oncoplastic or conventional breast-conserving surgery; exclusion criteria: 1. inflammatory breast cancer, stage iv breast cancer patients; 2. have other malignant tumors; 3. pregnancy women; 4. have severe co-morbidities that compromise the patients' compliance to our protocol, or endanger the patients; 5. refuse breast-conserving surgery.
efficacy of hypnotherapy for agoraphobia

Conditions: Agoraphobia

Summary: the purpose of the study is to compare the efficacy of hypnotherapy for the treatment of agoraphobia compared to a wait-list control group.

with the present study, the efficacy of 8-12 sessions of individual hypnotherapy will be compared to a wait-list control groups. at study entry and at the end of treatment with hypnotherapy, the agoraphobia symptoms will be assessed via clinician-rating and self-report. it is expected that hypnotherapy will be superior to a wait-list control regarding the percentage reduction of the anxiety symptoms after three months of treatment.

Eligibility criteria:
inclusion criteria: * written informed consent * patient fulfills dsm-5 (diagnostic and statistical manual of mental disorders) criteria for agoraphobia * 18 - 65 years of age * sufficient knowledge of the german language in order to participate in the study * sufficient availability to participate in weekly therapy sessions exclusion criteria: * acute suicidality (intended action, concrete plans or intermittent pronounced suicidal ideation) * lifetime diagnosis of a bipolar disorder or psychotic disorder * alcohol or substance use disorder without abstinence in the last 12 months * severe cognitive impairments (in cases of suspicion evaluation via mini mental state test (mmst) \< 26, will be conducted) * other severe primary mental disorders to be treated: severe major depressive disorder, severe personality disorder of borderline type with self-injury, severe combined personality disorder, actual posttraumatic stress disorder, anorexia nervosa, obsessive compulsive disorder * somatic disorder impeding participation in regular psychotherapy sessions * outpatient psychotherapy during the last twelve months. * medication with anxiolytics or anti-psychotics (antidepressant medication is permitted if stable since more than eight weeks and no planned changes during the duration of therapy)

Keywords: hypnosis wait-list